Načítá se...
Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
OBJECTIVE: Radium-223(223Ra) is indicated for patients (p) with metastatic castration resistant prostate cancer (mCRCP). OBJECTIVES: The aim of this study was to evaluate the role of baseline clinical variables associated with overall survival (OS) and toxicity of 223Ra. Its purpose was to identify...
Uloženo v:
| Vydáno v: | Int Braz J Urol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Sociedade Brasileira de Urologia
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7239273/ https://ncbi.nlm.nih.gov/pubmed/32213206 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1590/S1677-5538.IBJU.2019.0343 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|